PR104

DRUG5 trials

Sponsors

Proacta, Incorporated

Conditions

Acute Lymphocytic LeukemiaAcute Myelogenous LeukemiaLung CancerNon-Small Cell Lung CancerUnspecified Adult Solid Tumor, Protocol Specific

Phase 1

PR104 and G-CSF in Treating Patients With Solid Tumors

CompletedNCT00616213

Proacta, IncorporatedUnspecified Adult Solid Tumor, Protocol Specific

Start: 2008-02-29End: 2009-06-30Updated: 2011-06-01

PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia

Proacta, IncorporatedAcute Lymphocytic Leukemia, Acute Myelogenous Leukemia

Start: 2010-01-31End: 2012-12-31Target: 50Updated: 2012-08-31

A Phase I Dose Escalation Trial of PR104 Given Weekly in Subjects With Solid Tumors

CompletedNCT01358227

Proacta, IncorporatedUnspecified Adult Solid Tumor, Protocol Specific

Start: 2006-12-31End: 2010-01-31Updated: 2011-05-24

Phase 2

PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer

TerminatedNCT00544674

Proacta, IncorporatedLung Cancer

Start: 2007-08-31End: 2009-01-31Updated: 2012-12-10

Randomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC)

TerminatedNCT00862134

Proacta, IncorporatedNon-Small Cell Lung Cancer

Start: 2009-03-31End: 2010-05-31Updated: 2013-01-10

Related Papers

PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours.

2012-10-2545 citations